stable coronary artery disease
Conditions
Interventions
Qingxin jieyu group:On the basis of the basic treatment for SCAD, take Qingxin Jieyu granule twice a day, one bag each time, for a total of 6 months.
Control group:On the basis of the basic treatment for SCAD, take the placebo of Qingxin Jieyu granule twice a day, one bag each time, for a total of 6 months.
Sponsors
Xiyuan hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age ranging from 18 to 80 years old, regardless of gender; (2) Meeting the diagnostic criteria of SCAD: definite history of MI, or coronary angiography or coronary CTA confirming that at least one branch of the coronary artery has = 50% stenosis, or those with stable conditions = 1 month after ACS treatment (PCI or drug intervention); (3) TCM syndrome differentiation belongs to the syndrome of mutual accumulation of blood stasis and toxin syndrome; (4) Angina pectoris CCS classification is grade ? - ?; (5) The subjects are informed and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Uncontrolled hypertension despite medical treatment (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg); (2) Increased bleeding risk: history of previous hemorrhagic stroke; intracranial aneurysm; trauma or major surgery (including bypass surgery) within 1 month; currently suffering from active bleeding diseases, etc.; (3) Severe organic heart disease, such as patients with LVEF < 35% or NYHA/Killip cardiac function classification grade IV; (4) History of malignant arrhythmia within the recent 1 year (arrhythmia with hemodynamic impact, requiring drug or electrical cardioversion, or requiring cardiopulmonary resuscitation), history of congenital heart disease or malignancy, etc., which the researcher considers ineligible for the trial; (5) Severe liver and kidney dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 3×ULN or total bilirubin (TBIL) = 2×ULN; or creatinine clearance rate (Ccr < 30 ml/min); (6) Pregnant (pregnancy is defined as positive blood pregnancy test) or lactating women; (7) History of drug abuse or drug dependence within 1 year before screening; (8) Allergic constitution or allergy to known components of the investigational drug; (9) Other conditions that the researcher considers inappropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seattle Angina Questionnaire;Integral of TCM syndromes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Markers of inflammation;serum lipid parameter;cardiac function;ECG;major adverse cardiovascular events;cardiac uhrasonography;Secondary cardiovascular end points; | — |
Countries
China
Contacts
Public ContactGao zhuye
Xiyuan hospital
Outcome results
None listed